SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549
               

                                   FORM 8-K

                                CURRENT REPORT

                    Pursuant to Section 13 or 15(d) of the
                       Securities Exchange Act of 1934

                             September 26, 1997               
                Date of Report (date of earliest event reported)


                           CHEUNG LABORATORIES, INC.          
             (Exact name of Registrant as specified in its charter)

         Maryland                 000-14242               52-1256615   
      (State or other          (Commission File         (IRS Employer
      jurisdiction of          Number)                  Identification
      Incorporation)                                    Number)


                           10220-I Old Columbia Road
                         Columbia, Maryland  21045-1705
                    (Address of principal executive offices)


                                 410-290-5390                    
              (Registrant's telephone number, including area code)


ITEM 5: Other Information

    A.   PMA-Supplement granted for APA cancer treatment system

    On September 26, 1997, Cheung Laboratories, Inc. (the "Company") announced
that the FDA's Center for Devices and Radiological Health had granted 
premarket approval (PMA-Supplement) for a design change to the Company's 
Microfocus 1000 hyperthermia cancer treatment system to integrate patented 
technology using adaptive phase array targeting and nulling. The proprietary 
technology, developed by MIT, is expected to significantly improve the ability
of the system to focus heat, which is used in conjunction with radiation in 
the treatment of cancer.

    B.   Link Joins Board of Directors

    On October 9, 1997 the Company announced the appointment of Dr. Max Link
to its Board of Directors, filling a vacancy.

    Dr. Link, 57, has had an outstanding career in the pharmaceutical and 
biotechnology industries.  From 1993 to 1994, he served as Chief Executive 
Officer of Corange, Ltd., a leading medical diagnostics company recently 
acquired by Hoffman-LaRoche for $11.5 billion.  From 1971 to 1993, he held 
positions of increasing responsibility with Sandoz Pharma AG culminating
with his appointment as Chairman in 1992.

    At present, Dr. Link serves on the Boards of Human Genome Sciences, which
is engaged in research and development of novel proprietary pharmaceutical 
and diagnostic products based on the discovery and understanding of the 
medical utility of genes; Alexion Pharmaceuticals, a development stage 
company involved in the research and development of immunoregulatory
compounds; Cell Therapeutics, which discovers, develops and commercializes 
small molecule drugs for the treatment of cancer and inflammatory and immune
diseases; Access Pharmaceuticals, which provides drug delivery systems 
through the design of polymer drug complexes; Protein Design Laboratories, 
which develops human and humanized antibodies; Osiris Therapeutics, a company
that develops products to regenerate connective tissues; Procept, Inc. and 
Cytrx Corp.


                               SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the 
undersigned hereunto duly authorized.

                        CHEUNG LABORATORIES, INC.


   Dated: October 14, 1997       By \s\ Spencer J. Volk
                                    ----------------------------
                                 Name:  Spencer J.Volk      
                                 Title: President and Chief Executive Officer